Generic Name and Formulations:
Lipase 1200 Units, amylase 30000 Units, protease 30000 Units; caps.
Indications for KUTRASE:
Symptomatic treatment of digestive dysfunction.
May be opened and sprinkled on food. 1 cap with meals or snacks.
Glaucoma. GI or urinary tract obstruction. Paralytic ileus. Intestinal atony. Unstable cardiovascular status. Severe ulcerative colitis. Toxic megacolon. Myasthenia gravis. Acute pancreatic conditions. Pork allergy.
High environmental temperature. Diarrhea (may indicate obstruction). Autonomic neuropathy. Hyperthyroidism. Cardiovascular disease (esp. tachycardia). CHF. Arrhythmias. Hypertension. Renal disease. Hiatal hernia associated with reflux esophagitis. Avoid inhaling contents of caps. Pregnancy (Cat.C). Nursing mothers.
Avoid concomitant antacids.
Drowsiness, dizziness, blurred vision, other anticholinergic effects, suppression of lactation, paradoxical excitement, diarrhea.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML